{"entity":{"id":"nct06062810","kind":"trial","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","aka":[],"tldr":"A phase 2/3 trial of Raloxifene in advanced solid tumours, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.","summary":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT06062810 by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, with 600 participants enrolled, started 2025-06-21 and due to reach its primary completion in 2026-12-18. Interventions recorded: Raloxifene - Usual and Raloxifene - Study.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06062810","url":"https://clinicaltrials.gov/study/NCT06062810"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["raloxifene"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06062810","phase":"2/3","setting":"Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","enrolled":600,"outcomes":[]},"route":"/trials/nct06062810/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/"}]}}